← Evidence map

TrialAllergy2025

Diversity and Dosage Determine the Efficacy of the Probiotic SYN-53 in Allergic Rhinoconjunctivitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

Karl-Christian Bergmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Diversity and Dosage Determine the Efficacy of the Probiotic SYN-53 in Allergic Rhinoconjunctivitis: A Randomized, Double-Blind, Placebo-Controlled Trial. | OpenQuestion